

NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL

Lifeline Scientific, Inc. (“Lifeline” or “the Company”)

For immediate release

17 September 2007

This announcement does not constitute or form part of an offer, or any solicitation of an offer, for securities and any purchase of or application for shares in the placing should only be made on the basis of information contained in the formal admission document to be issued in connection with the placing and the admission to AIM.

Lifeline Scientific announces proposed AIM flotation and placing

Addressing the global problem of human donor organ shortage

Lifeline today announces its intention to seek admission to AIM with an institutional placing to raise approximately £7 million. Seymour Pierce Limited is acting as nominated adviser and broker to the Company. The Company is expected to have a market capitalisation upon listing of approximately £32 million.

Introduction

Lifeline Scientific is a medical device provider that is primarily focused on commercialising its LifePort product which enhances human kidney donor organ preservation, particularly during transport. LifePort addresses the global problem of human donor organ shortage.

Key Strengths

The LifePort system has a number of significant advantages over the most commonly used method for preserving donor organs:

- Improves the organ’s health status, which has been shown to improve transplant outcomes in terms of organ function and survival;
- Prolongs the organ’s useful life outside the body from +/- 18 hrs with a box of ice to +/- 48 hrs with LifePort, allowing more effective recovery from a wider donor population.

LifePort is thus a tool that can help increase the number of organs being made available for transplant and improves the quality of those organs.

The Product

The lead product, LifePort Kidney Transporter, is a machine-perfusion device for kidneys. It is FDA approved / CE marked, clinically validated and revenue-generating. The device is expected to replace for most uses the current standard method for kidney preservation, storage and transport – a static, cold storage based, ice-box approach. Machine-perfusion has been clinically demonstrated to increase the number of available donor organs by enabling more effective access to different categories of donor (non-heartbeating and Expanded Criteria donors), improve clinical outcomes and organ utilisation, and cut overall healthcare cost.

LifePort Kidney Transporter is already well accepted in the market place. It is currently in pilot introduction phase with 75 of the 300 key transplant centres worldwide and has generated revenues of approximately \$9m during this period.

Market Opportunity

There is a significant unmet need for donor kidneys. In 2006, there were 17,000 kidney transplants in the US, with a further 72,000 patients on the waiting list. The average wait for a kidney transplant in the US is 3.6 years. Annually, thousands of patients die waiting for a donor kidney. The dramatic supply/demand imbalance is similar for Europe and worldwide.

Further Products

In collaboration with key transplant centres in the US and Europe, other LifePort systems are in late stage development for the preservation and transport of the heart, lung, liver and pancreas.

Use of Proceeds and Growth Strategy

Marketed through the Company's Organ Recovery Systems division, the formal commercial launch of LifePort is due shortly. Growth will come from increasing the installed base of the equipment, higher utilisation of the equipment and consumables, and expanding the customer base geographically. The business model suggests recurring income mostly through consumable sales.

The IPO proceeds will principally be used to fund the full commercial launch of LifePort Kidney Transporter.

David Kravitz, Chief Executive of Lifeline, said:

"Lifeline Scientific is operating in an attractive area, relatively immune from downturns in the global economy, with a sustainable revenue business model and strong growth potential.

"Our LifePort Kidney Transporter has been well received in its pilot introduction phase in main transplant centres throughout the world. Initial indications suggest that LifePort has helped increase the number of transplantable donor kidneys and improved clinical outcomes, which reduces both the number of patients awaiting transplants and attendant healthcare costs. The IPO proceeds will enable us to fund the full commercial launch of the product in the world's key markets."

Enquiries:

Lifeline Scientific, Inc.

David Kravitz, CEO

Seymour Pierce

+44 (0)20 7107 8000

Mark Percy / Huaizheng Peng / Sarah Jacobs

Financial Dynamics

+44 (0)20 7831 3113

Ben Brewerton